港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

409.000

-2.600-0.63%

成交量：60.99萬

成交額：2.50億

市值：953.73億

市盈率：-311.37

高：418.600

開：417.800

低：403.800

收：411.600

52周最高：581.000

52周最低：152.000

股本：2.33億

香港流通股本：1.63億

量比：0.64

換手率：0.37%

股息：- -

股息率：- -

每股收益(LYR):-1.314

淨資產收益率：-17.56%

總資產收益率：-9.92%

市淨率：17.43

市盈率(LYR):-311.37

市銷率: 58.23

資料載入中...

總覽公司新聞公告

港股異動 | 生物技術股走弱，榮昌生物跌近12%

老虎资讯综合

生物製藥行業ESMO大會數據研究：聚焦ESMO大會：重磅彙報密集，國產新藥成為全場焦點

科倫博泰生物-B盤中異動股價大跌3.31%

【券商聚焦】天風證券維持科倫博泰生物-B(06990)「買入」評級指公司核心產品商業化進程順利

每日沽空追蹤 | 科倫博泰生物-B 10月22日沽空量成交3.23萬股，沽空比例為4.58%

三季報密集披露績優基金調倉曝光！任桀：全球雲計算產業仍然值得重點關注

交銀國際：維持科倫博泰生物-B(06990)「買入」評級目標價上升至549港元

科倫博泰生物-B盤中異動大幅上漲3.61%

ESMO炸場！中國ADC「一哥」亮劍

醫藥行業再傳捷報！科倫博泰重磅乳腺癌創新藥獲批上市

科倫博泰生物-B在ESMO總統會議上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04試驗積極結果同時發表在NEJM

港股異動 | 科倫博泰生物-B(06990)高開逾5% 於2025 ESMO大會上公佈佳泰萊®等多項臨牀研究成果

科倫博泰生物-B(06990)於2025年歐洲腫瘤內科學會大會上公佈的多項創新藥物研究成果

醫藥生物行業週報：醫療器械集採逐步體現「穩臨牀、保質量、防圍標、反內卷」的原則

蘆康沙妥珠單抗III期OptiTROP-Lung04研究成果於ESMO主席論壇環節和《新英格蘭醫學雜誌》同步發佈

科倫博泰生物-B(06990)：核心產品博度曲妥珠單抗治療2L+ HER2+乳腺癌獲國家藥品監督管理局批准上市

智通港股解盤 | 形勢有利匯率走強助推市場全面開花醫藥值得潛伏

科倫博泰生物，為什麼可以獨樹一幟。。。

每日沽空追蹤 | 科倫博泰生物-B 10月15日沽空量成交10.69萬股，沽空比例為9.74%

全球首個這個「温江造」靶向藥第三項適應症獲批

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":409,"timestamp":1762502884007,"preClose":411.6,"halted":0,"volume":609900,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.313649120309231,"marketStatus":"已收盤","change":-2.6,"latestTime":"11-07 16:08:04","open":417.8,"high":418.6,"low":403.8,"amount":250225948,"amplitude":0.035957,"askPrice":409,"askSize":300,"bidPrice":408.6,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-3.495030370439503,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1762738200000},"marketStatusCode":5,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":411.6,"openAndCloseTimeList":[[1762479000000,1762488000000],[1762491600000,1762502400000]],"volumeRatio":0.64195,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":162769979,"roa":"-9.92%","roe":"-17.56%","lyrEps":-1.313555,"volumeRatio":0.64195,"shares":233185969,"dividePrice":0,"high":418.6,"amplitude":0.035957,"preClose":411.6,"low":403.8,"week52Low":152,"pbRate":"17.43","psRate":"58.23","week52High":581,"institutionHeld":0,"latestPrice":409,"committee":0.142857,"eps":-1.3135546587363316,"divideRate":0,"volume":609900,"delay":0,"ttmEps":-3.4947790506151915,"open":417.8,"prevYearClose":163.3,"prevWeekClose":448,"prevMonthClose":448,"prevQuarterClose":514,"fiveDayClose":448,"twentyDayClose":510.5,"sixtyDayClose":403.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1755619200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-11-06","current":-117.031719,"percent":0.52,"low":-351.800852,"twenty":-203.932949,"median":-132.129081,"eighty":-48.609184,"high":-21.029201,"avg":-126.795211,"sd":82.579441,"marketCap":95979344840},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-06","current":-121.699468,"twenty":-203.932949,"median":-132.129081,"eighty":-48.609184,"marketCap":95979344840}],"updateTime":1762504851399},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152404472","title":"港股異動 | 生物技術股走弱，榮昌生物跌近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152404472","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152404472?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 13:25","pubTimestamp":1761197137,"startTime":"0","endTime":"0","summary":"10月23日，港股$生物(000504)$技术股盘中走弱，$荣昌生物(09995)$跌近12%，$药捷安康-B(02617)$跌超8%，$科伦博泰生物-B(06990)$跌超6%，$晶泰控股(02228)$、$映恩生物-B(09606)$跌近6%，$药明生物(02269)$、$康方生物(09926)$、$百济神州(06160)$跟跌。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df43def6c60d84e15ce9d1605944911d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228","06990","09606","ONC","09926","02269","09995","06160","02617"],"gpt_icon":0},{"id":"2577328718","title":"生物製藥行業ESMO大會數據研究：聚焦ESMO大會：重磅彙報密集，國產新藥成為全場焦點","url":"https://stock-news.laohu8.com/highlight/detail?id=2577328718","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577328718?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 10:07","pubTimestamp":1761185250,"startTime":"0","endTime":"0","summary":"中国药企重磅研究发布数量刷新历史记录，成为ESMO会议的全场焦点。2025年ESMO年会于欧洲当地时间10月17日至21日在德国柏林以线上+线下的形式举行，多项创新药研究在ESMO披露重磅数据，创新药行业迎来每年的重要投资窗口之一。投资建议与估值随着多款中国创新药数据在ESMO密集发布，且PD-1PLUS双抗、ADC等领域的临床数据达到国际领先水平，引起较高关注，或有望提振创新药新一轮的出海机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100743973d9752&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100743973d9752&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","01276","09995","09926","LU0359201612.USD","BK1191","LU1023057109.AUD","LU0359201885.HKD","06990","LU2543165471.USD"],"gpt_icon":0},{"id":"2577332552","title":"科倫博泰生物-B盤中異動 股價大跌3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332552?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 09:39","pubTimestamp":1761183598,"startTime":"0","endTime":"0","summary":"2025年10月23日早盘09时39分，科伦博泰生物-B股票出现异动，股价大幅下挫3.31%。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，药捷安康-B、永泰生物-B、复宏汉霖涨幅较大，振幅较大的相关个股有轩竹生物-B、药捷安康-B、三叶草生物-B，振幅分别为11.00%、10.36%、5.31%。该行的DCF目标价上升至549港元，维持科伦博泰生物-B“买入”评级，看好临床数据驱动下ADC产品矩阵的巨大全球价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102309395894d8b205&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102309395894d8b205&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2577344956","title":"【券商聚焦】天風證券維持科倫博泰生物-B(06990)「買入」評級 指公司核心產品商業化進程順利","url":"https://stock-news.laohu8.com/highlight/detail?id=2577344956","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577344956?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 09:19","pubTimestamp":1761182388,"startTime":"0","endTime":"0","summary":"金吾财讯 | 天风证券研报指出，近日，科伦博泰生物-B 核心产品sac-TMT在2025ESMO上公布了关于乳腺癌、非小细胞肺癌的两项重磅III期研究的积极结果，分别是HR+/HER2-BC2L适应症的OptiTROP-Breast02研究和EGFRTKI耐药后EGFR突变NSCLC患者的III期OptiTROP-Lung04研究。该机构表示，考虑到公司核心产品商业化进程顺利，该机构预计公司2025-2027年营业收入分别为20.84亿元、28.76亿元和46.63亿元；归母净利润分别为-6.22亿元、-1.30亿元和5.61亿元。维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968329","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","601162"],"gpt_icon":0},{"id":"2577657463","title":"每日沽空追蹤 | 科倫博泰生物-B 10月22日沽空量成交3.23萬股，沽空比例為4.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577657463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577657463?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 16:30","pubTimestamp":1761121836,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间10月22日，跌3.74%，卖空量成交3.23万股，较上一交易日减少76.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022163526a6c7948b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022163526a6c7948b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2577363429","title":"三季報密集披露 績優基金調倉曝光！任桀：全球雲計算產業仍然值得重點關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2577363429","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577363429?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 15:49","pubTimestamp":1761119351,"startTime":"0","endTime":"0","summary":"三季报密集披露，绩优基金调仓曝光公募三季报密集披露，绩优基金经理持仓动向备受市场关注。10月22日，前三季度“冠军基”、年内暴赚近195%的永赢科技智选，“翻倍基”长城医药产业精选等披露三季报，这些绩优基金大多重仓云计算、创新药等热门方向。截至三季度末，该基金保持高仓位运作，股票仓位超91%。在三季报中，任桀表示，全球云计算产业仍值得重点关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022154928a46dfbd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022154928a46dfbd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","01530","BK1161","BK1593","BK1583"],"gpt_icon":0},{"id":"2577308213","title":"交銀國際：維持科倫博泰生物-B(06990)「買入」評級 目標價上升至549港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577308213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577308213?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 14:31","pubTimestamp":1761114699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，基于监管审批进展，对Sac-TMT和博度曲妥珠销售有更乐观的预期，上调2025-27年收入预测0-5%、分别上调经PoS调整峰值预测至64亿/11亿元人民币。该行的DCF目标价上升至549港元，维持科伦博泰生物-B“买入”评级，看好临床数据驱动下ADC产品矩阵的巨大全球价值。该适应症的上市申请已于10月获批上市。2)KL166-III-06研究中，博度曲妥珠头对头战胜T-DM1，显著延长中位PFS。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"2577657253","title":"科倫博泰生物-B盤中異動 大幅上漲3.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577657253","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577657253?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 09:30","pubTimestamp":1761096608,"startTime":"0","endTime":"0","summary":"2025年10月22日早盘09时30分，科伦博泰生物-B股票出现波动，股价快速拉升3.61%。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.43%。其相关个股中，同源康医药-B、维升药业-B、和铂医药-B涨幅较大，振幅较大的相关个股有康诺亚-B、科伦博泰生物-B、君实生物，振幅分别为4.56%、1.91%、1.64%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022093008a6c6cecb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022093008a6c6cecb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2576851949","title":"ESMO炸場！中國ADC「一哥」亮劍","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851949?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 20:18","pubTimestamp":1760962692,"startTime":"0","endTime":"0","summary":"本次ESMO大会上，TROP2 ADC芦康沙妥珠单抗有两项III期临床研究入选LBA并作口头报告，均为支持新适应症上市的关键临床数据。OptiTROP-Lung04旨在评估芦康沙妥珠单抗单药对比培美曲塞联合铂类用于经EGFR-TKI治疗失败的EGFR突变NSCLC患者的有效性和安全性。这一积极结果，使其成为全球首个针对二线EGFR突变型NSCLC人群实现PFS与OS双重获益的ADC药物，填补了该治疗领域长期存在的关键空白。胃癌是全球发病率第五、死亡率第四的恶性肿瘤，而中国更是胃癌高发国家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","BK4080","LU0196878994.USD","ADC","BK4231"],"gpt_icon":0},{"id":"2576396258","title":"醫藥行業再傳捷報！科倫博泰重磅乳腺癌創新藥獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576396258","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576396258?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 11:15","pubTimestamp":1760930156,"startTime":"0","endTime":"0","summary":"10月17日，国家药品监督管理局发布消息，四川科伦博泰生物医药股份有限公司申报的注射用博度曲妥珠单抗获批上市，用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。乳腺癌作为一种常见的恶性肿瘤，严重威胁女性健康。舒泰莱的获批上市将为相关乳腺癌患者患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020112043a6c2d5c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020112043a6c2d5c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06978","06990","BK1161","BK1574"],"gpt_icon":0},{"id":"1135350783","title":"科倫博泰生物-B在ESMO總統會議上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04試驗積極結果同時發表在NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=1135350783","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135350783?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 10:02","pubTimestamp":1760925730,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B在ESMO总统会议上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04试验积极结果同时发表在NEJM","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2576888757","title":"港股異動 | 科倫博泰生物-B(06990)高開逾5% 於2025 ESMO大會上公佈佳泰萊®等多項臨牀研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2576888757","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576888757?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 09:26","pubTimestamp":1760923585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B(06990)高开逾5%，截至发稿，涨5.37%，报483港元，成交额159.39万港元。消息面上，科伦博泰生物-B发布公告，本公司已在于10月17日至21日在德国柏林举行的2025年欧洲肿瘤内科学会(ESMO)大会上公布多项临床研究成果，涵盖靶向人滋养细胞表面抗塬2(TROP2)抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰莱®)、靶向人类表皮生长因子受体2(HER2)ADC博度曲妥珠单抗(亦称A166)(舒泰莱®)以及Claudin18.2 (CLDN18.2) ADC SKB315的相关数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2576700736","title":"科倫博泰生物-B(06990)於2025年歐洲腫瘤內科學會大會上公佈的多項創新藥物研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2576700736","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576700736?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 08:19","pubTimestamp":1760919598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司已在于10月17日至21日在德国柏林举行的2025年欧洲肿瘤内科学会(ESMO)大会上公布多项临床研究成果，涵盖靶向人滋养细胞表面抗塬2(TROP2)抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰莱®)、靶向人类表皮生长因子受体2(HER2)ADC博度曲妥珠单抗(亦称A166)(舒泰莱®)以及Claudin18.2 (CLDN18.2) ADC SKB315的相关数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","06990","BK1574","LU0196878994.USD","06978"],"gpt_icon":0},{"id":"2576839675","title":"醫藥生物行業週報：醫療器械集採逐步體現「穩臨牀、保質量、防圍標、反內卷」的原則","url":"https://stock-news.laohu8.com/highlight/detail?id=2576839675","media":"中邮证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576839675?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 00:00","pubTimestamp":1760889600,"startTime":"0","endTime":"0","summary":"本周主题医疗器械集采逐步体现“稳临床、保质量、防围标、反内卷”的原则。恒生医疗保健指数下跌5.85%，板块整体跑输恒生指数1.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第11 位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102016003194d37168&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102016003194d37168&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09997","01093","BK1574","01530","LU0196878994.USD","06990","01801","BK1222","BK1583","BK1100","BK1161","09996"],"gpt_icon":0},{"id":"2576004292","title":"蘆康沙妥珠單抗III期OptiTROP-Lung04研究成果於ESMO主席論壇環節和《新英格蘭醫學雜誌》同步發佈","url":"https://stock-news.laohu8.com/highlight/detail?id=2576004292","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576004292?lang=zh_tw&edition=fundamental","pubTime":"2025-10-19 23:43","pubTimestamp":1760888580,"startTime":"0","endTime":"0","summary":"2025年10月19日，科伦博泰宣布，在2025年ESMO年会上，张力教授公布了靶向TROP2的ADC药物芦康沙妥珠单抗用于EGFR突变非小细胞肺癌的III期OptiTROP-Lung04研究结果，该结果同步发表于《新英格兰医学杂志》。研究积极结果支持芦康沙妥珠单抗获NMPA批准上市，用于治疗经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020010839973726a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020010839973726a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2576066082","title":"科倫博泰生物-B(06990)：核心產品博度曲妥珠單抗治療2L+ HER2+乳腺癌獲國家藥品監督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576066082","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576066082?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 16:39","pubTimestamp":1760690399,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司靶向人类表皮生长因子受体2的抗体偶联药物博度曲妥珠单抗(舒泰莱)获国家药品监督管理局 批准用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。本公司已启动博度曲妥珠单抗用于治疗既往接受过有效载荷为拓扑异构酶抑制剂ADC治疗的HER2+不可切除或转移性BC的开放、多中心2期临床研究。据悉，博度曲妥珠单抗是一款用于治疗晚期HER2+实体瘤的差异化HER2 ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物-B(06990)：核心产品博度曲妥珠单抗治疗2L+ HER2+乳腺癌获国家药品监督管理局批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2575784139","title":"智通港股解盤 | 形勢有利匯率走強助推 市場全面開花醫藥值得潛伏","url":"https://stock-news.laohu8.com/highlight/detail?id=2575784139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575784139?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 20:10","pubTimestamp":1760530225,"startTime":"0","endTime":"0","summary":"汇率走强，利好航空。昨日板块聚焦提到了机器人，今日市场有传闻称，特斯拉已向中国供应商三花智控下达了价值6.85亿美元的Optimus线性执行器订单。当前与特斯拉合作进展顺利，但具体细节因保密协议暂无法披露。国庆期间，蜜雪冰城宣布以2.97亿元人民币总价，收购鲜啤福鹿家53%股权。资金已经提前开始潜伏。公司进入2025年，势头更为强劲。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","09939","LU0348825331.USD","BK1589","LU1861219969.SGD","GELYY","BK1515","IE00BZ08YT58.USD","00175","LU0348784397.USD","LU0315179316.USD","159938","LU1720050803.USD","IE00BZ08YR35.GBP","LU0293314216.USD","LU1861214812.USD","LU2778985437.USD","LU1961090484.USD","LU0417516738.SGD","IE00B543WZ88.USD","BK1119","BK1521","LU0348735423.USD","LU0348766576.USD","LU0348827113.USD","LU0634319403.HKD","09926","06990","LU0540923850.HKD","SG9999002828.SGD","80175","LU0348783233.USD","LU1282651048.USD","LU0196878994.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU1224444064.USD","LU0561508036.HKD","BK1161","IE00B5MMRT66.SGD","LU0417516902.SGD","IE00B0JY6N72.USD","LU2488822045.USD","LU2476274720.SGD","LU1282651121.HKD","BK1539","LU2399975544.HKD","LU2476274308.USD","LU0348767384.USD","EVS.SI"],"gpt_icon":1},{"id":"2575732856","title":"科倫博泰生物，為什麼可以獨樹一幟。。。","url":"https://stock-news.laohu8.com/highlight/detail?id=2575732856","media":"粒场","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575732856?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 19:19","pubTimestamp":1760527196,"startTime":"0","endTime":"0","summary":"经粒场统计，2023年百利天恒、科伦博泰分别上涨了386.61%和69.8%；2024年两者涨幅为37.05%、58.7%。2022年1月-2023年3月，科伦博泰生物完成3次，至多9个ADC项目与MSD的授权合作，总交易金额近118亿美元。2025年以来，百利天恒涨幅达77.47%，科伦博泰涨幅更是高达186.96%。这也是全球首款于LC领域获得上市批准的TROP2 ADC药物。2025年6月，sac-TMT联合塔戈利单抗获得国家药监局突破性疗法认定，用于一线治疗驱动基因阴性的局部晚期或转移性非鳞状NSCLC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015215235a6baed40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015215235a6baed40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2575328837","title":"每日沽空追蹤 | 科倫博泰生物-B 10月15日沽空量成交10.69萬股，沽空比例為9.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328837","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328837?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 16:30","pubTimestamp":1760517044,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间10月15日，涨5.02%，卖空量成交10.69万股，较上一交易日减少18.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015163508a6ba75f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015163508a6ba75f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2575732888","title":"全球首個這個「温江造」靶向藥第三項適應症獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2575732888","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575732888?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 15:33","pubTimestamp":1760513580,"startTime":"0","endTime":"0","summary":"四川科伦博泰的靶向药芦康沙妥珠单抗（sac-TMT，佳泰莱®）获国家药品监督管理局批准第三项适应症，用于治疗经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。该药是迄今全球首个且唯一对比含铂双药化疗显示显著总生存期获益，并获批用于仅接受过TKI治疗后进展的晚期NSCLC的ADC药物。作为科伦博泰核心产品，sac-TMT是全球首个在肺癌适应症获批上市的TROP2 ADC药物。本次批准基于一项III期临床研究，研究显示sac-TMT在OS和PFS方面均实现显著改善。科伦博泰首席执行官表示，该适应症获批将为更多TKI耐药患者提供精准高效的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101516051594ca666b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101516051594ca666b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":196,"code":"91000000","status":"200"}]}}